New circulating biomarkers for prostate cancer.

Area of Science:

• Urology
• Oncology
• Biomarker Discovery

Background:

• Prostate-specific antigen (PSA) revolutionized prostate cancer (PCa) screening but faces limitations in specificity and prognostic value.
• Changes in PCa epidemiology have further complicated the interpretation and utility of PSA.
• There is a critical need for improved methods to detect PCa and predict disease course.

Purpose of the Study:

• To review novel approaches for improving PCa detection and prognosis beyond traditional PSA testing.
• To discuss a select group of promising blood-based biomarkers for PCa.
• To highlight the potential of biomarker panels for clinical decision-making.

Main Methods:

• Review of existing literature on PSA derivatives and novel blood biomarkers for PCa.
• Discussion of candidate biomarkers including human glandular kallikrein, IGF-I and its binding proteins, and others.
• Analysis of the potential role of these markers in improving PCa diagnosis and prognosis.

Main Results:

• Various PSA derivatives (e.g., PSA density, velocity, isoforms) have been explored to enhance specificity.
• Numerous novel blood biomarkers (e.g., human glandular kallikrein, IGF-I, urokinase plasminogen activation system) show promise in early studies.
• No single biomarker currently offers sufficient certainty for dictating treatment decisions.

Conclusions:

• Future PCa prognosis and management may rely on panels of biomarkers rather than single markers.
• Biomarker panels could enhance accuracy in predicting PCa presence, stage, and metastasis.
• These panels may serve as prognosticators and surrogate endpoints for treatment response.